Elan and Wyeth change bapineuzumab dosing over safety concern
This article was originally published in Scrip
Executive Summary
Elan and Wyeth have discontinued the highest (2.0mg/kg) of three dosing regimens in two ongoing Phase III studies of bapineuzumab. The studies involve patients with mild to moderate Alzheimer's disease who do not carry the apolipoprotein E4 (ApoE4) allele, and the changes follow concerns about vasogenic oedema.